<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25181" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Minoxidil</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nessel</surname>
            <given-names>Trevor A.</given-names>
          </name>
          <aff>MSU College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kumar D</surname>
            <given-names>Dinesh</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Trevor Nessel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dinesh Kumar D declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25181.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Minoxidil, also known as 2,4-pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide, was initially developed in the 1970s as a potent peripheral vasodilator agent for the treatment of severe refractory hypertension.&#x000a0;Minoxidil exerts its antihypertensive effect by opening adenosine triphosphate (ATP)-sensitive potassium channels,&#x000a0;thereby reducing peripheral resistance and lowering blood pressure levels in patients. However, owing to the significant adverse effects of taking oral minoxidil, this drug is currently used only for patients with resistant hypertension who&#x000a0;do not adequately respond to the maximum doses of 3 different classes of&#x000a0;antihypertensive medications. In 1987, a topical formulation of minoxidil was developed to treat androgenic alopecia, initially targeting males and later expanding its use to include females. This activity comprehensively reviews the indications, contraindications, mechanism of action, pharmacokinetics, adverse effects, and other crucial aspects of topical and oral minoxidil therapy in a clinical setting.&#x000a0;This activity aims to improve the collaboration and the&#x000a0;competence of the interprofessional&#x000a0;healthcare team members&#x000a0;to&#x000a0;provide&#x000a0;quality&#x000a0;care for patients experiencing hair loss and resistant hypertension.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between oral and topical minoxidil therapy based on patients' medical history, risk factors, and specific conditions.</p></list-item><list-item><p>Screen patients' eligibility considering contraindications and potential drug interactions before prescribing minoxidil.</p></list-item><list-item><p>Assess patients' response to minoxidil therapy, monitoring for adverse effects, therapeutic outcomes, and patient satisfaction.</p></list-item><list-item><p>Communicate with patients about minoxidil therapy, explaining its potential benefits, risks, expected outcomes, and self-monitoring techniques to enable shared decision-making among healthcare providers.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25181&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25181">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25181.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Minoxidil, also known as 2,4-pyrimidinediamine,6-(1-piperidinyl)-, 3-oxide, was initially developed as a potent peripheral vasodilator agent for treating severe refractory hypertension. However, owing to the significant adverse effects&#x000a0;of oral minoxidil use, this drug is currently used only for patients with resistant hypertension who&#x000a0;do not adequately respond to the maximum doses of 3 different antihypertensive medications.</p>
        <p>Furthermore, approximately one-fifth of patients undergoing oral minoxidil treatment developed hypertrichosis. In 1987, a topical formulation of minoxidil was developed to treat androgenic alopecia, initially targeting males and later expanding its use to include females. This&#x000a0;topic focuses on the clinical application of topical minoxidil therapy for androgenic alopecia and oral minoxidil therapy for resistant hypertension.<xref ref-type="bibr" rid="article-25181.r1">[1]</xref><xref ref-type="bibr" rid="article-25181.r2">[2]</xref></p>
        <p>Topical minoxidil is available in both liquid solution and foam formulations. The liquid form of topical minoxidil contains alcohol and propylene glycol, the 2 crucial molecules that help dissolve the drug in a patient's body, facilitating&#x000a0;tissue absorption.&#x000a0;Formulations containing 2% and 5% minoxidil commonly treat scalp alopecia in individuals aged 18 and above. Long-term use of minoxidil is necessary to uphold the achieved clinical outcomes of the medication, as these effects diminish when the drug is discontinued.<xref ref-type="bibr" rid="article-25181.r3">[3]</xref><xref ref-type="bibr" rid="article-25181.r4">[4]</xref></p>
        <p>
<bold>Topical Minoxidil</bold>
</p>
        <p>Androgenic alopecia is the only indication approved by the U.S. Food and Drug Administration (FDA) for topical minoxidil.</p>
        <p>Off-label uses of topical minoxidil are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Alopecia areata: Minoxidil has demonstrated the ability to elicit a favorable clinical response when used as a standalone treatment for alopecia areata or in conjunction with other medications, such as corticosteroids.</p>
          </list-item>
          <list-item>
            <p>Chemotherapy-induced alopecia: In this case, minoxidil has exhibited the capacity to reduce hair loss and expedite the process of hair regrowth.</p>
          </list-item>
          <list-item>
            <p>Hair transplant: Hair loss, also known as telogen effluvium, is a common observation after a hair transplant. Minoxidil can be used before and after hair transplantation to reduce hair loss in patients. However, the treatment should be temporarily suspended for 3 days before the hair transplant to prevent excessive bleeding.</p>
          </list-item>
          <list-item>
            <p>Scarring alopecia:&#x000a0;Minoxidil has displayed evidence of having an antifibrotic effect on this condition. Consequently, topical minoxidil treatment could be a viable therapeutic option during the initial stages of dermatoses, leading to scarring alopecia, such as those stemming from scalp burns.</p>
          </list-item>
          <list-item>
            <p>Monilethrix: Minoxidil induces the synchronization of hair follicles entering the anagen phase in patients experiencing this condition.</p>
          </list-item>
          <list-item>
            <p>Hereditary alopecia or hypotrichosis: Minoxidil has demonstrated its beneficial effects by promoting hair shaft thickening in hypotrichosis.</p>
          </list-item>
        </list>
        <p>
<bold>Oral Minoxidil</bold>
</p>
        <p>According to the American College of Cardiology and the American Heart&#x000a0;Association (AHA), resistant hypertension is characterized by elevated blood pressure levels exceeding the target range, despite the simultaneous utilization of 3 different classes of antihypertensive medications. These classes typically include a combination of a calcium channel blocker, a renin-angiotensin-aldosterone system blocker (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker), and a diuretic. These drugs&#x000a0;are&#x000a0;administered at the highest daily doses a patient can tolerate. The FDA approves minoxidil for&#x000a0;maintaining blood pressure&#x000a0;levels in patients with resistant hypertension.<xref ref-type="bibr" rid="article-25181.r5">[5]</xref></p>
        <p>Many forms of alopecia are off-label indications for oral or sublingual minoxidil. Recently, multiple studies have explored using low-dose oral minoxidil (&#x0003c;5 mg daily) for treating many forms of alopecia, including male-patterned and female-patterned hair loss, to treat hair loss without&#x000a0;adverse reactions.<xref ref-type="bibr" rid="article-25181.r6">[6]</xref>&#x000a0;The low adverse-effect profile of low-dose oral minoxidil aids in long-term adherence to treatment and positive clinical response.<xref ref-type="bibr" rid="article-25181.r7">[7]</xref><xref ref-type="bibr" rid="article-25181.r8">[8]</xref>&#x000a0;More studies are needed to test the efficacy of&#x000a0;oral and sublingual minoxidil&#x000a0;when treating various alopecia to improve patient outcomes and provide an alternative for those with difficulty with topical formulations.<xref ref-type="bibr" rid="article-25181.r6">[6]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-25181.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Topical minoxidil, with the empirical formula C<sub>9</sub>H<sub>15</sub>N<sub>5</sub>O, is a stimulant for hair growth (see <bold>Image.</bold> Skeletal Formula of Minoxidil). The precise mechanism of action for the drug remains inadequately understood. The sulfotransferase enzyme in the human scalp converts minoxidil into minoxidil sulfate, which is the active form of the molecule. Differences in sulfotransferase activity among individuals can affect minoxidil's effectiveness, leading to inconsistencies in the therapy.<xref ref-type="bibr" rid="article-25181.r9">[9]</xref>&#x000a0;</p>
        <p>Minoxidil shortens the telogen phase to prompt the dormant hair follicles&#x000a0;for premature transition into the anagen phase. The shortening of the telogen phase might lead to telogen effluvium following minoxidil therapy. Furthermore, minoxidil extends the anagen phase, resulting in increased hair length and thickness, thereby representing the observable outcomes of minoxidil therapy.<xref ref-type="bibr" rid="article-25181.r10">[10]</xref></p>
        <p>The initial outcomes of minoxidil become apparent after approximately 8 weeks of initiating the treatment, with the maximum effects manifesting around 4 months. Minoxidil affects the potassium channels present in vascular smooth muscles and hair follicles.<xref ref-type="bibr" rid="article-25181.r10">[10]</xref>&#x000a0;This potassium channel activity&#x000a0;may induce the following effects:</p>
        <list list-type="bullet">
          <list-item>
            <p>Stimulation of the microcirculation around the hair follicles&#x000a0;induces arteriolar vasodilation,&#x000a0;thereby encouraging conditions conducive to hair growth.</p>
          </list-item>
          <list-item>
            <p>Induction of the vascular endothelial growth factor expression leads&#x000a0;to heightened vascularization around the hair follicles, thereby promoting&#x000a0;hair growth.</p>
          </list-item>
          <list-item>
            <p>Activation of the prostaglandin-endoperoxide synthase-1 enzyme leads&#x000a0;to the enhancement of hair growth.</p>
          </list-item>
          <list-item>
            <p>Inhibition of androgen-related effects on androgen-sensitive hair follicles.</p>
          </list-item>
          <list-item>
            <p>Direct stimulation&#x000a0;of the hair follicles as the drug acts&#x000a0;as an epidermal growth factor on the matrix cells, slowing their aging process&#x000a0;and extending their anagen phase. This process is achieved through the activation of the beta-catenin pathway.</p>
          </list-item>
          <list-item>
            <p>Display of antifibrotic characteristics due to its impact on collagen synthesis.</p>
          </list-item>
        </list>
        <p>
<bold>Hypertension</bold>
</p>
        <p>Minoxidil exerts its antihypertensive effect by opening adenosine triphosphate (ATP)-sensitive potassium channels. As a result, when the smooth muscle vasculature is relaxed, it reduces peripheral resistance, which ultimately helps to lower blood pressure levels. Consequently, this process increases plasma renin activity, which, in turn, triggers salt and water retention in a patient's body. Additionally, minoxidil triggers the activation of the sympathetic nervous system, resulting in tachycardia and&#x000a0;heightened&#x000a0;cardiac output. Therefore, clinicians prescribe beta-blockers and diuretics alongside minoxidil to mitigate potential adverse effects.<xref ref-type="bibr" rid="article-25181.r5">[5]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Absorption: Minoxidil is absorbed from the gastrointestinal tract at&#x000a0;a&#x000a0;rate of 95%, and the drug achieves peak levels within the initial hour. Conversely, only 1.4% of topical minoxidil is absorbed through the skin.<xref ref-type="bibr" rid="article-25181.r7">[7]</xref></p>
        <p>Distribution: Minoxidil shows no binding affinity to plasma proteins.&#x000a0;This drug experiences broad distribution, with a distribution volume ranging from 2.8 to 3.3 L/kg.</p>
        <p>Metabolism:&#x000a0;Minoxidil undergoes metabolism through conjugation, sulfation, and hydroxylation processes. The resulting metabolites generally exhibit lower pharmacological activity&#x000a0;than the parent&#x000a0;drug. Notably, as previously mentioned, topical minoxidil is metabolized within the hair follicles by the sulfotransferase enzyme, leading to the formation of minoxidil sulfate.<xref ref-type="bibr" rid="article-25181.r11">[11]</xref></p>
        <p>Elimination: Although the&#x000a0;elimination half-life of minoxidil is around 3 to 4 hours, the hypotensive impact of the medication&#x000a0;may persist for up to 72 hours. Notably, the excretion of minoxidil and its metabolites predominantly occurs through the kidneys.<xref ref-type="bibr" rid="article-25181.r12">[12]</xref></p>
      </sec>
      <sec id="article-25181.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Minoxidil is available as an over-the-counter topical agent in the United States.&#x000a0;Furthermore, the medication is marketed in an oral tablet&#x000a0;formulation and as a topical agent in foam and solution formulations for both male and female patients.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Topical minoxidil:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients can apply a 5% aerosol formulation of topical minoxidil directly onto their scalp at a one-half capful dose. The medication&#x000a0;should be used twice daily by male patients&#x000a0;and once daily by female patients.</p>
          </list-item>
          <list-item>
            <p>Women should apply 1 mL of the 2% topical minoxidil solution to their scalp twice daily.</p>
          </list-item>
          <list-item>
            <p>Men should apply 1 mL of 2% or 5% topical minoxidil solution to their scalp twice&#x000a0;daily.</p>
          </list-item>
        </list>
        <p>Scalp massage is not required following the application of the medication. Minoxidil uptake reaches approximately 50% within an hour and increases to 75% after 4 hours. Although certain practitioners use microneedling with topical minoxidil to potentially enhance the drug's efficacy,&#x000a0;further studies are necessary to evaluate the potential significance of this practice.<xref ref-type="bibr" rid="article-25181.r13">[13]</xref><xref ref-type="bibr" rid="article-25181.r14">[14]</xref><xref ref-type="bibr" rid="article-25181.r15">[15]</xref>&#x000a0;</p>
        <p>A 2% topical minoxidil solution is effective for male patients experiencing androgenic alopecia in their frontotemporal and vertex regions. However, the 5% topical minoxidil solution&#x000a0;provides a more significant clinical benefit than the 2% solution. The clinical response to minoxidil is notably more pronounced when the onset of alopecia occurs within 5 years, primarily among young adults, and when the hair follicles are not extensively miniaturized.<xref ref-type="bibr" rid="article-25181.r16">[16]</xref>&#x000a0;</p>
        <p>Oral minoxidil:&#x000a0;</p>
        <p>This&#x000a0;formulation is supplied in tablet formulations, with options of 2.5 mg and 10 mg doses. Although the FDA does not approve the oral formulation of minoxidil for treating hair loss in individuals, clinical trials have demonstrated its effectiveness at dosages ranging from 0.25 to 2.5 mg daily for maintaining blood pressure&#x000a0;levels in patients with resistant hypertension.<xref ref-type="bibr" rid="article-25181.r8">[8]</xref></p>
        <p>The recommended initial dosage of minoxidil for hypertensive therapy is 5 mg, administered once daily to patients younger than 12, which can be gradually escalated up to a maximum of 40 mg per day. Higher doses should be equally divided and administered to individuals 2 or 3 times daily to prevent excessive hypotension. The maximum recommended dosage of oral minoxidil is 100 mg per day.<xref ref-type="bibr" rid="article-25181.r12">[12]</xref> As per the AHA's guidelines for managing resistant hypertension, minoxidil should be prescribed alongside a loop diuretic and a beta-blocker to mitigate potential adverse effects in patients.<xref ref-type="bibr" rid="article-25181.r2">[2]</xref></p>
        <p>The recommended off-label dosing of oral minoxidil for treating alopecia is 0.25 to 2.5 mg, administered once or twice&#x000a0;daily in 1 or 2 equally divided doses.</p>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p>Patient with hepatic impairment: The product labeling for topical or oral minoxidil does not offer specific dosage adjustment information. However, caution is advised when considering its use in such cases.</p>
        <p>Patient with renal impairment:&#x000a0;When dosing oral minoxidil, it is advisable to consider dose reduction for individuals with renal impairment. However, specific dosage adjustment information is not supplied for topical minoxidil.</p>
        <p>Pregnancy considerations: As animal reproductive studies have indicated specific adverse effects of minoxidil in pregnant women, it is not advisable to use this drug. Minoxidil holds an FDA pregnancy category C classification.<xref ref-type="bibr" rid="article-25181.r17">[17]</xref></p>
        <p>Breastfeeding considerations: As minoxidil is excreted in breast milk, its use is not recommended&#x000a0;in breastfeeding women.<xref ref-type="bibr" rid="article-25181.r10">[10]</xref></p>
        <p>Pediatric patients:&#x000a0;The recommended initial dosage of oral minoxidil in patients younger than 12 is 0.2 mg/kg&#x000a0;daily. Typically, the maintenance dosage of minoxidil ranges from 0.25 to 1 mg/kg per day, and the maximum recommended dosage is 50 mg per day.<xref ref-type="bibr" rid="article-25181.r18">[18]</xref> Clinicians&#x000a0;may suggest topical minoxidil in children; however, it is considered an off-label drug indication.<xref ref-type="bibr" rid="article-25181.r19">[19]</xref></p>
        <p>Older&#x000a0;patients:&#x000a0;Oral minoxidil should be initiated at a lower dose in older patients as clinicians recommend, considering comorbidities,&#x000a0;polypharmacy, and increased risk of falls in this population.&#x000a0;</p>
      </sec>
      <sec id="article-25181.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Although minoxidil is generally well tolerated, topical minoxidil is associated with the following adverse effects, as listed below.<xref ref-type="bibr" rid="article-25181.r10">[10]</xref><xref ref-type="bibr" rid="article-25181.r20">[20]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Minoxidil-induced telogen effluvium: The shortening of the telogen phase caused by minoxidil can result in excessive hair shedding&#x000a0;in individuals.</p>
          </list-item>
          <list-item>
            <p>Skin irritation: This condition can lead to erythema, discomfort, and a burning sensation on the scalp.</p>
          </list-item>
          <list-item>
            <p>Scaly changes of the scalp: This condition can entail irritation or a potential worsening of seborrheic dermatitis.</p>
          </list-item>
          <list-item>
            <p>Isolated&#x000a0;pruritus: appears in the area of application.</p>
          </list-item>
          <list-item>
            <p>Allergic contact dermatitis: This can lead to symptoms such as erythema, eczematous skin reactions, and pruritus. Minoxidil and propylene glycol are the primary allergens implicated in cases of allergic contact dermatitis. Patch testing can aid in identifying the underlying causative agent. If allergic contact dermatitis arises due to propylene glycol, topical minoxidil as a foam formulation can be an alternative option, as it does not contain propylene glycol.</p>
          </list-item>
          <list-item>
            <p>Localized or generalized hypertrichosis: Both oral and topical minoxidil usage can lead to hypertrichosis. However, this effect is more frequently observed with the oral formulation and&#x000a0;when&#x000a0;the 5% topical minoxidil solution is used compared to&#x000a0;the 2% solution. Research indicates that hypertrichosis is linked to minoxidil extending the anagen phase. In addition, cases of hypertrichosis have been documented in infants due to unintentional direct skin contact.<xref ref-type="bibr" rid="article-25181.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>Oral minoxidil is also associated with significant adverse effects, as listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Rare but severe reactions include pericarditis, pericardial effusion, cardiac tamponade, exacerbating congestive heart failure, and worsening angina.</p>
          </list-item>
          <list-item>
            <p>Oral minoxidil administration can lead to significant hypotension and potential complications such as thrombocytopenia and leukopenia in individuals taking the medication.<xref ref-type="bibr" rid="article-25181.r22">[22]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Breast tenderness and gynecomastia have also been reported as adverse effects of the medication.<xref ref-type="bibr" rid="article-25181.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Hypertrichosis, edema, tachycardia, and weight gain&#x000a0;are also caused by&#x000a0;oral minoxidil.</p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Systemic cyclosporine can exacerbate adverse effects such as hypertrichosis when combined with topical minoxidil. Notably, hypertrichosis symptoms significantly improved after discontinuing topical minoxidil for 2 months.<xref ref-type="bibr" rid="article-25181.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Coadministration of low-dose aspirin and&#x000a0;minoxidil may diminish the effectiveness of topical minoxidil. This decrease in effectiveness is attributed to the inhibitory effect of low-dose&#x000a0;aspirin&#x000a0;on sulfotransferase enzymes in human hair.<xref ref-type="bibr" rid="article-25181.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Concurrent use of guanethidine with&#x000a0;minoxidil can&#x000a0;cause severe hypotension.<xref ref-type="bibr" rid="article-25181.r26">[26]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25181.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Minoxidil should not be used in patients with a known history of hypersensitivity to the drug or its constituents, including propylene glycol.</p>
          </list-item>
          <list-item>
            <p>The utilization of minoxidil is not recommended for pregnant and breastfeeding women. Although minoxidil is not recognized as a teratogenic agent, there are occasional reports of congenital anomalies.<xref ref-type="bibr" rid="article-25181.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>The product intended for use in males is not recommended for use in females.</p>
          </list-item>
          <list-item>
            <p>This product is also contraindicated in patients younger than 18 and those who experience sudden, uncertain, or patchy hair loss, hair loss after childbirth, scalp infections or inflammation, or use another scalp medication.</p>
          </list-item>
        </list>
        <p>
<bold>Box Warning&#x000a0;</bold>
</p>
        <p>Oral minoxidil can cause serious adverse effects, including pericardial effusion, that can advance to cardiac&#x000a0;tamponade. Reports of angina pectoris worsening have also been reported in patients using the medication. As a result, careful oversight is imperative when administering minoxidil to patients.<xref ref-type="bibr" rid="article-25181.r27">[27]</xref>&#x000a0;</p>
        <p>Patients receiving guanethidine should be admitted to a hospital for monitoring when minoxidil is administered due to the substantial risk of severe orthostatic hypotension.<xref ref-type="bibr" rid="article-25181.r26">[26]</xref> Coadministration of beta-blockers with minoxidil is advised to help manage the elevated myocardial workload and tachycardia.<xref ref-type="bibr" rid="article-25181.r12">[12]</xref>&#x000a0;Oral minoxidil should be used with a loop diuretic to prevent severe fluid accumulation in a patient's body.<xref ref-type="bibr" rid="article-25181.r28">[28]</xref></p>
      </sec>
      <sec id="article-25181.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients using topical minoxidil should undergo regular monitoring for any alterations in the scalp and the occurrence of localized or generalized hypertrichosis.<xref ref-type="bibr" rid="article-25181.r29">[29]</xref>&#x000a0;Hypotension is a rare occurrence in patients using topical minoxidil. Nonetheless,&#x000a0;some clinicians advise consistent monitoring of blood pressure, heart rate, and electrocardiographic changes&#x000a0;for patients undergoing topical minoxidil therapy. Clinicians should conduct thorough assessments to eliminate secondary causes of hypertension, such as renal artery stenosis, primary aldosteronism, pheochromocytoma, and Cushing syndrome, warranting minoxidil treatment. Regular monitoring of fundoscopic examination, renal function, echocardiogram, and ankle-brachial index is recommended to assess potential target organ damage for patients taking the medication.<xref ref-type="bibr" rid="article-25181.r2">[2]</xref></p>
      </sec>
      <sec id="article-25181.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Percutaneous toxicity is a rare occurrence following standard minoxidil application. In cases of significant oral ingestion, there is currently no recognized antidote for minoxidil toxicity. Unintentional oral consumption of minoxidil may lead to vomiting and, in rare instances, necessitate hospitalization. Instances of hypotension, tachycardia, and changes in the electrocardiogram have been reported following accidental ingestion. Intravenous fluids and pharmaceutical vasopressors can address&#x000a0;malignant hypotension. In substantial inadvertent minoxidil ingestion, gastric lavage technique and activated charcoal administration might be essential to avert systemic toxicity in patients.<xref ref-type="bibr" rid="article-25181.r30">[30]</xref>&#x000a0;</p>
        <p>A case was<bold>&#x000a0;</bold>reported where a&#x000a0;young girl&#x000a0;unintentionally&#x000a0;ingested a topical solution of&#x000a0;minoxidil prescribed to her father. After ingesting the medication, the girl encountered adverse effects such as hypotension and prolonged tachycardia.<xref ref-type="bibr" rid="article-25181.r31">[31]</xref> Intravenous fluids are essential in cases of oral minoxidil overdose, causing hypotension in individuals. Vasopressors should be administered to patients for hypotension that does not respond to standard treatment.<xref ref-type="bibr" rid="article-25181.r32">[32]</xref><xref ref-type="bibr" rid="article-25181.r33">[33]</xref></p>
      </sec>
      <sec id="article-25181.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Topical minoxidil has been a trusted medication in the medical field for more than 30 years and is commonly prescribed by dermatologists, primary care physicians, nurse practitioners, and physician assistants. Minoxidil is also prescribed as a treatment option for resistant hypertension in patients. According to AHA, it&#x000a0;is recommended to consult hypertension specialists for cases of resistant hypertension. A retrospective study demonstrated enhanced blood pressure control in patients with resistant hypertension under the care of hypertension specialists.<xref ref-type="bibr" rid="article-25181.r5">[5]</xref><xref ref-type="bibr" rid="article-25181.r34">[34]</xref><xref ref-type="bibr" rid="article-25181.r35">[35]</xref>&#x000a0;</p>
        <p>Secondary causes of hypertension require consultation with nephrologists and endocrinologists. Pharmacists are critical in ensuring no potential drug-drug interactions are of concern in patients with hypertension. Although minoxidil is regarded as a primary treatment option to promote hair growth, the efficacy of the medication can vary inconsistently depending on various cases.&#x000a0;Some patients experience substantial improvements, whereas others observe only minimal changes. Healthcare professionals should inform patients that individual responses to minoxidil can vary and constant adherence to medication is crucial for optimal hair growth.</p>
        <p>Emergency medicine and critical care physicians should focus on stabilizing the patient in case of a&#x000a0;minoxidil overdose. To ensure the best outcomes for patients receiving minoxidil therapy for alopecia and hypertension, physicians, advanced practice practitioners, specialists, pharmacists, and nursing staff must work collaboratively, utilizing an interprofessional approach and open communication to facilitate effective teamwork to achieve optimal outcomes with the fewest adverse events.</p>
      </sec>
      <sec id="article-25181.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25181&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25181">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25181/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25181">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25181.s11">
        <fig id="article-25181.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Skeletal Formula of Minoxidil Contributed by Public Domain (Wikimedia)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Minoxidil" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25181.s12">
        <title>References</title>
        <ref id="article-25181.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jimenez-Cauhe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saceda-Corralo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rodrigues-Barata</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hermosa-Gelbard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moreno-Arrones</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Fernandez-Nieto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Va&#x000f1;o-Galvan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>81</volume>
            <issue>2</issue>
            <fpage>648</fpage>
            <page-range>648-649</page-range>
            <pub-id pub-id-type="pmid">31054970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Calhoun</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Daugherty</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Dennison-Himmelfarb</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Egan</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Flack</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Judd</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lackland</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Laffer</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Newton-Cheh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Textor</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Turan</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <collab>American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council</collab>
            </person-group>
            <article-title>Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>72</volume>
            <issue>5</issue>
            <fpage>e53</fpage>
            <page-range>e53-e90</page-range>
            <pub-id pub-id-type="pmid">30354828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tegta</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Negi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A Study to Compare the Efficacy of Platelet-rich Plasma and Minoxidil Therapy for the Treatment of Androgenetic Alopecia.</article-title>
            <source>Int J Trichology</source>
            <year>2019</year>
            <season>Mar-Apr</season>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>68</fpage>
            <page-range>68-79</page-range>
            <pub-id pub-id-type="pmid">31007475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gajjar</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Barvaliya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sonagra</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Comparative Study between Mesotherapy and Topical 5% Minoxidil by Dermoscopic Evaluation for Androgenic Alopecia in Male: A Randomized Controlled Trial.</article-title>
            <source>Int J Trichology</source>
            <year>2019</year>
            <season>Mar-Apr</season>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>58</fpage>
            <page-range>58-67</page-range>
            <pub-id pub-id-type="pmid">31007474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mundt</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Matenaer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lammert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000f6;ttmann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kr&#x000e4;mer</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Birck</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Benck</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Minoxidil for Treatment of Resistant Hypertension in Chronic Kidney Disease--A Retrospective Cohort Analysis.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>1162</fpage>
            <page-range>1162-1167</page-range>
            <pub-id pub-id-type="pmid">27246772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ram&#x000ed;rez-Mar&#x000ed;n</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Tosti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Role of Oral Minoxidil in Patterned Hair Loss.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2022</year>
            <season>Nov-Dec</season>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>729</fpage>
            <page-range>729-733</page-range>
            <pub-id pub-id-type="pmid">36386734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Talukder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Venkataraman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bamimore</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Minoxidil: a comprehensive review.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>1896</fpage>
            <page-range>1896-1906</page-range>
            <pub-id pub-id-type="pmid">34159872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Randolph</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tosti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Oral minoxidil treatment for hair loss: A review of efficacy and safety.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>737</fpage>
            <page-range>737-746</page-range>
            <pub-id pub-id-type="pmid">32622136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freire</surname>
                <given-names>PCB</given-names>
              </name>
              <name>
                <surname>Riera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Martimbianco</surname>
                <given-names>ALC</given-names>
              </name>
              <name>
                <surname>Petri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Atallah</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>Minoxidil for patchy alopecia areata: systematic review and meta-analysis.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>1792</fpage>
            <page-range>1792-1799</page-range>
            <pub-id pub-id-type="pmid">30835901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suchonwanit</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thammarucha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leerunyakul</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Minoxidil and its use in hair disorders: a review.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2019</year>
            <volume>13</volume>
            <fpage>2777</fpage>
            <page-range>2777-2786</page-range>
            <pub-id pub-id-type="pmid">31496654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Goren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Miot</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Oral minoxidil bio-activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern hair loss.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>e40</fpage>
            <page-range>e40-e41</page-range>
            <pub-id pub-id-type="pmid">31420889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sica</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Minoxidil: an underused vasodilator for resistant or severe hypertension.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2004</year>
            <month>May</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>283</fpage>
            <page-range>283-7</page-range>
            <pub-id pub-id-type="pmid">15133413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dhurat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tr&#x000fc;eb</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Va&#x000f1;&#x000f3;-Galv&#x000e1;n</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kovacevic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Situm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McCoy</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes.</article-title>
            <source>Dermatol Ther</source>
            <year>2019</year>
            <month>May</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>e12915</fpage>
            <pub-id pub-id-type="pmid">30974011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sung</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Juhasz</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Mesinkovska</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-160</page-range>
            <pub-id pub-id-type="pmid">30794366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fabbrocini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cantelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Masar&#x000e0;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Annunziata</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Marasca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cacciapuoti</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.</article-title>
            <source>Int J Womens Dermatol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>203</fpage>
            <page-range>203-211</page-range>
            <pub-id pub-id-type="pmid">30627618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Messenger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dobos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Reygagne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Finner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blumeyer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trakatelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tosti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Del Marmol</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Piraccini</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Nast</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blume-Peytavi</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-22</page-range>
            <pub-id pub-id-type="pmid">29178529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smorlesi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caldarella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caramelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Di Lollo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moroni</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Topically applied minoxidil may cause fetal malformation: a case report.</article-title>
            <source>Birth Defects Res A Clin Mol Teratol</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>67</volume>
            <issue>12</issue>
            <fpage>997</fpage>
            <page-range>997-1001</page-range>
            <pub-id pub-id-type="pmid">14745922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyers</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Siu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy review of chronic pediatric hypertension.</article-title>
            <source>Clin Ther</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>10</issue>
            <fpage>1331</fpage>
            <page-range>1331-56</page-range>
            <pub-id pub-id-type="pmid">21982385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>XF</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>A poor performance in comprehensive geriatric assessment is associated with increased fall risk in elders with hypertension: a cross-sectional study.</article-title>
            <source>J Geriatr Cardiol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>113</fpage>
            <page-range>113-8</page-range>
            <pub-id pub-id-type="pmid">25870613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cantisani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Melis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Iorio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scali</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Calvieri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Minoxidil use in dermatology, side effects and recent patents.</article-title>
            <source>Recent Pat Inflamm Allergy Drug Discov</source>
            <year>2012</year>
            <month>May</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>130</fpage>
            <page-range>130-6</page-range>
            <pub-id pub-id-type="pmid">22409453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rica Echevarr&#x000ed;a</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a Del Monte</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delgado Rubio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arcangeli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lotti</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Severe hypertrichosis in infants due to transdermic exposure to 5% and 7% topical minoxidil.</article-title>
            <source>Dermatol Ther</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>e14230</fpage>
            <pub-id pub-id-type="pmid">32844481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e1;nchez-D&#x000ed;az</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Delgado</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Montero-V&#x000ed;lchez</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Salvador-Rodr&#x000ed;guez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Molina-Leyva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tercedor-S&#x000e1;nchez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arias-Santiago</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Systemic Minoxidil Accidental Exposure in a Paediatric Population: A Case Series Study of Cutaneous and Systemic Side Effects.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>Sep</month>
            <day>20</day>
            <volume>10</volume>
            <issue>18</issue>
            <pub-id pub-id-type="pmid">34575367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r23">
          <label>23</label>
          <element-citation publication-type="book">
            <chapter-title>Minoxidil</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>1</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">31643713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sever</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sonmez</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Kocak</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Limited use of minoxidil in renal transplant recipients because of the additive side-effects of cyclosporine on hypertrichosis.</article-title>
            <source>Transplantation</source>
            <year>1990</year>
            <month>Sep</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>536</fpage>
            <pub-id pub-id-type="pmid">2402807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dhurat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Situm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacevic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lukinovic Skudar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Goldust</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lotti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McCoy</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients.</article-title>
            <source>Dermatol Ther</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>e12741</fpage>
            <pub-id pub-id-type="pmid">30226287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mutterperl</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Lowenthal</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Long-term effects of minoxidil in the treatment of malignant hypertension in chronic renal failure.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1976</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>10 Pt 1</issue>
            <fpage>498</fpage>
            <page-range>498-509</page-range>
            <pub-id pub-id-type="pmid">789412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oye</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oye</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Signs of early cardiac tamponade induced by Minoxidil.</article-title>
            <source>Am J Emerg Med</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>40</volume>
            <fpage>226.e1</fpage>
            <page-range>226.e1-226.e2</page-range>
            <pub-id pub-id-type="pmid">32778436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gbadamosi</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Melvin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Atypical Case of Minoxidil-Induced Generalized Anasarca and Pleuropericardial Effusion.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>e15424</fpage>
            <pub-id pub-id-type="pmid">34249570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gargallo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gutierrez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vanaclocha</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Guerra-Tapia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Generalized Hypertrichosis Due to Topical Minoxidil.</article-title>
            <source>Actas Dermosifiliogr</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>106</volume>
            <issue>7</issue>
            <fpage>599</fpage>
            <page-range>599-600</page-range>
            <pub-id pub-id-type="pmid">25688008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacMillan</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Warshawski</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Minoxidil overdose.</article-title>
            <source>Chest</source>
            <year>1993</year>
            <month>Apr</month>
            <volume>103</volume>
            <issue>4</issue>
            <fpage>1290</fpage>
            <page-range>1290-1</page-range>
            <pub-id pub-id-type="pmid">8131492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <article-title>Topical minoxidil: accidental poisoning in children.</article-title>
            <source>Prescrire Int</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>159</issue>
            <fpage>97</fpage>
            <pub-id pub-id-type="pmid">25941701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garrard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sollee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aaronson</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Refractory hypotension due to Rogaine&#x000ae; (minoxidil) ingestion managed with midodrine.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>49</volume>
            <issue>10</issue>
            <fpage>907</fpage>
            <page-range>907-9</page-range>
            <pub-id pub-id-type="pmid">22077158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chakar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Salter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Minoxidil overdose with hypotension effectively managed with norepinephrine, rather than dopamine.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-134</page-range>
            <pub-id pub-id-type="pmid">36779868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Denker</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Townsend</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Blood pressure control 1 year after referral to a hypertension specialist.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>9</issue>
            <fpage>624</fpage>
            <page-range>624-9</page-range>
            <pub-id pub-id-type="pmid">24034654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25181.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garg</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Folker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Izhar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>HR</given-names>
              </name>
              <collab>RUSH University Hypertension Service</collab>
            </person-group>
            <article-title>Resistant hypertension revisited: a comparison of two university-based cohorts.</article-title>
            <source>Am J Hypertens</source>
            <year>2005</year>
            <month>May</month>
            <volume>18</volume>
            <issue>5 Pt 1</issue>
            <fpage>619</fpage>
            <page-range>619-26</page-range>
            <pub-id pub-id-type="pmid">15882544</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
